BOSTON — Three hearings in Boston and Washington, D.C. will focus on whether a deadly outbreak of fungal meningitis traced to a Framingham compounding pharmacy could have been prevented.
BOSTON — The director was fired for ignoring a complaint that a Framingham company linked to a deadly meningitis outbreak was shipping drugs in bulk, in violation of its state license.
WASHINGTON — The subpoena comes after Barry Cadden, co-founder of New England Compounding Center, reportedly declined to appear before Congress next week.
BOSTON — Regulators ordered all pharmacists and technicians who worked at the company at the center of the meningitis outbreak to stop working in the drug-compounding industry.
BOSTON — Federal regulators say that further testing has found bacteria in products made by a Framingham pharmacy linked to the deadly fungal meningitis outbreak.
BOSTON — The emergency regulations allow the state to monitor whether the specialty pharmacies are operating more like drug manufacturing facilities.
BOSTON — Lawmakers will hold hearings looking into the Department of Public Health’s handling of the meningitis outbreak and drug lab scandal.
BOSTON — Ameridose is a sister company of New England Compounding Center, the pharmacy at the center of the meningitis outbreak.
BOSTON — The firm sent customers a “report card” touting the cleanliness of its labs, even though internal tests showed widespread contamination.
BOSTON — The Department of Public Health shut down a compounding pharmacy in Waltham after a surprise inspection prompted by the nationwide meningitis outbreak linked to a different company.